A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors
A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors
Active, not recruiting · NCT06480240 · Registry updated 2025-08-08Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors | Advanced Solid Tumor | Active, not recruiting | Phase 1 / Phase 2 | 2025-08-08 | NCT06480240 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| OBI Pharma, Inc | 4 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| California Clinical Trials Medical Group (CCTMG) | Glendale | United States | 2 |
| Karmanos Cancer Institute | Detroit | United States | 153 |
| NEXT Oncology | San Antonio | United States | 70 |
| NEXT Virginia | Fairfax | United States | 83 |
| Scripps Green Hospital | La Jolla | United States | 14 |
| Taipei Medical University - Shuang Ho Hospital | New Taipei City | Taiwan | 1 |
| Taipei Tzu Chi Hospital | New Taipei City | Taiwan | 1 |
| The University of Texas MD Anderson Cancer Center | Houston | United States | 207 |